Hairy cell leukemia: Short review, today's recommendations and outlook

Blood Cancer Journal

Volumn 4, Issue 2, 2014, Pages

  Maevis, V ^a   Mey, U ^b   Schmidt Wolf, G ^a   Schmidt Wolf, I G H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

cladribine; hairy cell leukemia; immunotoxins; pentostatin; rituximab

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BENDAMUSTINE; CD20 ANTIGEN; CD22 ANTIBODY; CD22 ANTIGEN; CLADRIBINE; FLAVOPIRIDOL; FLUDARABINE; IMMUNOMODULATING AGENT; IMMUNOTOXIN; IMMUNOTOXIN LMB2; PENTOSTATIN; RITUXIMAB; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BONE MARROW; BONE MARROW SUPPRESSION; BRAF V600E GENE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CELLULITIS; CYTOPENIA; CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAIRY CELL LEUKEMIA; HEART ARREST; HEART ARRHYTHMIA; HERPES ZOSTER; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IRRADIATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MISSENSE MUTATION; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATHOGENESIS; PHOTOSENSITIVITY; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; PRURITUS; PYROSEQUENCING; RASH; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; SPLEEN; SPLENECTOMY; SPLENIC IRRADIATION; SPLENOMEGALY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84895441321     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.3     Document Type: Review

References (117)

1. Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H et al. Advances in the treatment of hairy-cell leukaemia. Lancet Oncol 2003; 4: 86-94.
2. Gedik E, Girgin S, Aldemir M, Keles C, Tuncer M, Aktas A. Non-traumatic splenic rupture: report of seven cases and review of the literature. Gastroenterology 2008; 14: 6711-6716.
3. Lavrenkov K, Krepel-Volsky S, Levi I, Ariad S. Low dose palliative radiotherapy for splenomegaly in hematologic disorders. Leuk Lymphoma 2011; 53: 430-434.
4. Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 660-666.
5. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 2011; 52: 18-20.
6. Golomb HM. Fifty years of hairy cell leukemia treatments. Leuk Lymphoma 2011; 52: 3-5.
7. Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer 2010; 116: 4788-4792.
8. Daver N, Nazha A, Kantarjian H, Haltom R, Ravandi F. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clin lymphoma, myeloma leuk 2012; 13: 86-89.
9. Barth J, Rummel MJ. Haarzellleukämie: teil 1: krankheitsbild und allgemeine therapie. Med Monatsschr Pharm 2009; 32: 249-251.
10. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 2012; 156: 186-195.
11. Gujral S, Lad P, Subramanian PG, Shet TM, Epari S, Laskar S et al. Histopathological audit of splenectomies received at a cancer hospital. Indian J Pathol Microbiol 2011; 54: 487-496.
12. Adeniji BA, Fallas M, Incerpi M, Hamburg S, Katz R, Ogunyemi D. Laparoscopic splenectomy for hairy cell leukemia in pregnancy. Case Rep Med 2010; 2010: Article ID 136823 (e-pub).
13. Rizack T, Mega A, Legare R, Castillo J. Management of hematological malignancies during pregnancy. Am J Hematol 2009; 84: 830-841.
14. Lauria F, Cencini E, Forconi F. Alternative methods of cladribine administration. Leuk Lymphoma 2011; 52: 34-37.
15. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals 2010; 3: 994-1015.
16. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984; 310: 15-18.
17. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992; 80: 466-471.
18. Grever MR. Hairy cell leukemia: a successful model for experimental therapeutics-pentostatin and new ideas. Leuk Lymphoma 2011; 52: 25-28.
19. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol 2011; 29: 583-590.
20. Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Exp Opin Invest Drugs 2009; 18: 1169-1181.
21. Shouval R, Duffield A, Gocke C, Lee L, Brodsky RA. Pentostatin-induced hypereosinophilia with eosinophilic gastroenteritis. Leuk Lymphoma 2010; 51: 1567-1569.
22. Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma 2011; 52: 43-45.
23. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-2986.
24. Maloisel F, Benboubker L, Gardembas M, Coiffier B, Divine M, Sebban C et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17: 45-51.
25. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 2011; 52: 21-24.
26. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZS, Johnson SAN et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740.
27. Grever MR. How I treat hairy cell leukemia. Blood 2010; 115: 21-28.
28. Austein T, Schmitt A. 50-jähriger Mann mit Gewichtsverlust und Splenomegalie. Dtsch Med Wochenschr (1946) 2009; 134: 251-252.
29. Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leuk Lymphoma 2009; 50: 12-17.
30. Torrey ML, Sigal DS, Saven A. Development of cladribine at Scripps for hairy cell leukemia and current results. Leuk Lymphoma 2011; 52: 29-33.
31. Singh V, Chittappen KP, Gudi V, Bénardais K, Voss EV, Stangel M. 2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol 2013; 173: 288-297.
32. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007-3015.
33. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
34. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-896.
35. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476-1481.
36. Chadha P, Rademaker AW, Mendiratta P, Kim B, Evanchuk DM, Hakimian D et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241-246.
37. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109: 3672-3675.
38. Zenhäusern R, Schmitz SH, Solenthaler M, Heim D, Meyer-Monard S, Hess U et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 2009; 50: 1501-1511.
39. Naik RR, Saven A. My treatment approach to hairy cell leukemia. Mayo Clin Proc 2012; 87: 67-76.
40. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010; 115: 1893-1896.
41. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012; 119: 1988-1991.
42. Lauria F, Forconi F. Combination therapies to improve the long-term outcome in hairy cell leukemia. Leuk Lymphoma 2009; 50: 18-22.
43. Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009; 114: 4696-4702.
44. Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol 2011; 29: 55-66.
45. Caligaris-Cappio F. IG genes and hairy cell leukemia. Blood 2009; 114: 4610-4611.
46. Forconi F, Cencini E, Sozzi E, Sicuranza A, Raspadori D, Lauria F. Insight into the behavior of hairy cell leukemia by immunogenetic analysis. Leuk Lymphoma 2011; 52: 103-107.
47. Forconi F, Cencini E, Sicuranza A, Sozzi E, Lauria F. Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. Leuk Lymphoma 2011; 52: 15-23.
48. Juliusson G, Samuelsson H. Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. Leuk Lymphoma 2011; 52: 46-49.
49. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma 2011; 52: 50-52.
50. Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: current concepts. Cancer invest 2008; 26: 860-865.
51. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007; 99: 215-222.
52. Damaj G, Kuhnowski F, Marolleau J, Bauters F, Leleu X, Yakoub-Agha I. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 2009; 83: 246-250.
53. Girardi K, Paviglianiti A, Cirillo M, Bianchi A, Gherardi G, Annibali O et al. Tuberculous meningoencephalitis in a patient with hairy cell leukemia in complete remission. J Clin Exp Hematopathol 2012; 52: 31-34.
54. Ganzel C, Gatt ME, Maly A, Ben-Yehuda D, Goldschmidt N. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine. Leuk Lymphoma 2012; 53: 1169-1173.
55. Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJP, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 2011; 52: 82-86.
56. Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB. Response of hairy cell leukemia to bendamustine. Leuk Lymphoma 2011; 52: 1153-1156.
57. Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A et al. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma 2011; 52: 79-81.
58. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M et al. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. J Clin Oncol 2012; 30: 1822-1828.
59. Park JH, Levine RL. Targeted immunotherapy for hairy cell leukemia. J Clin Oncol 2012; 30: 1888-1890.
60. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011; 17: 6398-6405.
61. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 2011; 108: 5742-5747.
62. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol 2001; 115: 609-611.
63. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86: 1046-1050.
64. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810-813.
65. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906-3911.
66. Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007; 48: 2441-2443.
67. Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008; 143: 296-298.
68. Zenhäusern R, Simcock M, Gratwohl A, Hess U, Bargetzi M, Tobler A. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica 2008; 93: 1426-1428.
69. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011; 118: 3818-3823.
70. Else M, Dearden CE, Matutes E, Forconi F, Lauria F, Ahmad H et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011; 52: 75-78.
71. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-1636.
72. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, Fitzgerald DJP, Wilson WH et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719-6729.
73. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJP, Wilson WH et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27: 2983-2990.
74. Leung K. Cy5.5-Rituximab. Molecular Imaging and Contrast Agent Database (MICAD) [Internet] 10 March 2009 [updated 4 June 2009]. National Center for Biotechnology Information (US): Bethesda, MD, USA; 2004-2013.
75. Fey MF. Rekombinante Proteine als Therapeutika in derklinischen Onkologie. Ther Umsch 2011; 68: 618-630.
76. Malfuson JV, Fagot T, Konopacki J, Souleau B, Cremades S, Revel Tde. Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta haematol 2010; 123: 110-116.
77. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6-14.
78. Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma 2011; 52: 72-74.
79. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49-53.
80. Else M, Osuji N, Forconi F, Dearden C, Del Giudice I, Matutes E et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007; 110: 2240-2247.
81. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009; 23: 1-13.
82. Kreitman RJ, Fitzgerald DJP, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma 2009; 50: 32-37.
83. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305-2315.
84. Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2011; 119: 192-195.
85. Tiacci E, Pucciarini A, Bigerna B, Pettirossi V, Strozzini F, Martelli MP et al. Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia. Blood 2012; 119: 5332-5333.
86. Weston-Bell NJ, Hendriks D, Sugiyarto G, Bos NA, Kluin-Nelemans HC, Forconi F et al. Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. Leukemia 2013; 27: 241-245.
87. Burger JA. BRAF mutation: supporting diversity in HCL. Blood 2012; 119: 3193-3194.
88. Tadmor T, Tiacci E, Falini B, Polliack A. The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. Leuk Lymphoma 2012; 53: 2339-2340.
89. Rinaldi A, Kwee I, Young KH, Zucca E, Gaidano G, Forconi F et al. Genome-wide high resolution DNA profiling of hairy cell leukaemia. Br J Haematol 2013; 162: 566-569.
90. Ping N, Wang Q, Wang Q, Dong S, Wu L, Xue Y et al. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. Leuk Lymphoma 2012; 53: 2498-2499.
91. Tiacci E, Schiavoni G, Martelli MP, Boveri E, Pacini R, Tabarrini A et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica 2013; 98: 635-639.
92. Takahashi Y, Mori J, Kami M. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 365: 960-961; author reply 961-962.
93. Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 365: 961; author reply 961-962.
94. Auer RL, Cotter FE. A defining moment for hairy cell leukaemia. Br J Haematol 2011; 155: 607-608.
95. Blombery P, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 2011; 97: 780-783.
96. Trifa AP, Popp RA, Cucuianu A, Coada? CA, Urian LG, Militaru MS et al. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. Leuk Lymphoma 2012; 53: 2496-2497.
97. Berghoff AS, Capper D, Preusser M. Lack of BRAF V600E protein expression in primary central nervous system lymphoma. Appl Immunohistochem Mol Morphol 2013; 21: 351-353.
98. Laurini JA, Aoun P, Iqbal J, Chan W, Greiner TC. Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders. Am J Clin Pathol 2012; 138: 877-883.
99. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012; 119: 3330-3332.
100. Lennerz JK, Klaus BM, Marienfeld RB, Möller P. Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E. Br J Haematol 2012; 157: 267-269.
101. Langabeer SE, O'Brien D, McElligott AM, Lavin M, Browne PV. BRAF V600E-Negative Hairy Cell Leukaemia. Case Rep Hematol 2013; 2013: 513049.
102. Boyd EM, Bench AJ, van Veer MB 't, Wright P, Bloxham DM, Follows GA et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol 2011; 155: 609-612.
103. Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2011; 119: 188-191.
104. Szankasi P, Reading NS, Vaughn CP, Prchal JT, Bahler DW, Kelley TWA. Quantitative Allele-Specific PCR Test for the BRAF V600E Mutation Using a Single Heterozygous Control Plasmid for Quantitation: A Model for qPCR Testing without Standard Curves. J Mol Diagn 2013; 15: 248-254.
105. Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol 2012; 138: 153-156.
106. Andrulis M, Penzel R, Weichert W, Deimling A von, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Sugr Pathol 2012; 36: 1796-1800.
107. Warden DW, Ondrejka S, Lin J, Durkin L, Bodo J, Hsi ED. Phospho-ERKTHR202/Tyr214 Is Overexpressed in Hairy Cell Leukemia and Is a Useful Diagnostic Marker in Bone Marrow Trephine Sections. Am J Sugr Pathol 2013; 37: 305-308.
108. Dietrich S, Glimm H, Andrulis M, Kalle C, von, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038-2040.
109. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D et al. Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. J Clin Oncol 2013; 31: e300-e303.
110. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 2013; 98: e20-e22.
111. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2012; 161: 150-153.
112. Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S et al. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget 2012; 3: 1688-1699.
113. Jones JA, Kraut EH, Deam D, Byrd JC, Grever MR. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia. Leuk Lymphoma 2012; 53: 490-491.
114. Sivina M, Kreitman RJ, Arons E, Buggy JJ, Ravandi F, Burger JA. Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) blocks hairy cell leukemia (HCL) survival, proliferation, and BCR signaling: a new therapeutic approach for HCL. American Society of Hematology 2012; CLL -Therapy, excluding Transplantation: Poster I: 1802.
115. Kiyasu J, Shiratsuchi M, Ohtsuka R, Sada E, Idutsu K, Nagasawa E et al. Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation. In Hematol 2009; 89: 403-405.
116. Zinzani PL, Bonifazi F, Pellegrini C, Casadei B, Argnani L, Motta MR et al. Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. Clin lymphoma, myeloma & leukemia 2012; 12: 287-289.
117. Cheever MA, Fefer A, Greenberg PD, Appelbaum F, Armitage JO, Buckner CD et al. Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. N Engl J Med 1982; 307: 479-481.